CellGen
Leiden, Netherlands· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $105M
Overview
A European biotech developing engineered cell therapies for cancer and immune diseases.
OncologyImmunology
Technology Platform
A proprietary cell engineering platform for creating next-generation immune cell therapies with enhanced functionality and safety profiles.
Funding History
1Total raised:$105M
Series B$105M
Opportunities
Potential to address significant unmet needs in solid tumors or autoimmune diseases with an innovative cell therapy approach, commanding high value.
Risk Factors
Faces substantial technical, manufacturing, and clinical development risks inherent to complex cell therapies, along with high burn rates.
Competitive Landscape
Faces intense competition from well-funded global biotechs and pharma in the rapidly evolving cell therapy space, particularly in next-generation CAR-T and solid tumor applications.